多学科综合中医治疗晚期非小细胞肺癌855例回顾性研究
该回顾性研究分析855例晚期非小细胞肺癌患者接受多学科综合中医治疗后的无进展生存期(PFS)与中位生存时间(MST),并筛选影响进展和预后的因素。结果显示PFS为9.0个月、MST为26.0个月,1、2、3、5年生存率分别为79.2%、54%、36.2%、17.1%。多因素分析提示性别、病理类型、临床分期为独立预后危险因素,手术史、放疗、中成药疗程、中药注射液静滴、中药汤剂口服时长及干预措施为独立保护因素。
要点
- 晚期NSCLC综合中医治疗后PFS 9.0个月、MST 26.0个月。
- 女性、腺癌、IIIb-IIIc期患者结局最佳。
- 手术史、放疗及中药汤剂口服时长等为独立保护因素。
核心结论
- 女性患者较男性进展风险更低、预后更好;年轻患者进展风险更高但长期预后优于老年患者。
- 体能状态评分较低者进展风险更低、预后更好。
- 综合中医治疗可显著降低晚期NSCLC进展风险、改善预后并延长生存时间,较单纯支持治疗有额外优势。
研究设计与样本
- 采用Kaplan-Meier法及log-rank序贯检验进行单因素分析,对单因素显著变量用Cox回归模型进行多因素分析。
- 筛选与进展和预后相关的关键因素,建立Cox比例风险模型计算预后指数。
主要发现
- 855例晚期NSCLC患者PFS为9.0个月,MST为26.0个月。
- 1、2、3、5年生存率分别为79.2%、54%、36.2%、17.1%。
- 性别、病理类型、临床分期为独立预后危险因素;手术史、放疗、中成药疗程、中药注射液静滴、中药汤剂口服时长及干预措施为独立预后保护因素。
- 性别是进展的独立危险因素,手术史和中药汤剂口服时长是独立保护因素(均P<0.05)。
- 女性IIIb-IIIc期肺腺癌患者结局最佳。
临床怎么用
- 对晚期NSCLC患者可考虑在多学科框架下综合运用中成药、中药注射液及中药汤剂等中医干预。
- 关注性别、病理类型、临床分期、体能状态评分及手术史、放疗史等因素进行预后分层。
- 中药汤剂口服时长与中成药疗程等治疗持续性因素与更好预后相关,临床中应重视足疗程管理。
局限性
- 本研究为单中心回顾性研究,可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effects of multidisciplinary and comprehensive Chinese medicine (CM) treatments on progression-free survival (PFS) and median survival time (MST) in patients with advanced non-small cell lung cancer (NSCLC) and identify factors that influence progression and prognosis. METHODS: Clinical data of 855 patients with advanced NSCLC who received multidisciplinary and comprehensive CM treatments at Longhua Hospital from January 2009 to December 2018 were retrospectively analyzed. Univariate analysis was performed by the Kaplan-Meier method and log-rank sequential inspection. Multivariate analysis of significant variables from the univariate analysis was performed with Cox regression modeling. Key factors correlated to progression and prognosis were screened out, and a Cox proportional hazard model was established to calculate the prognostic index. RESULTS: The PFS and MST of 855 advanced NSCLC patients were 9.0 and 26.0 months, respectively. The 1-, 2-, 3-, and 5-year survival rates were 79.2%, 54%, 36.2%, and 17.1%, respectively. Gender, pathologic type, and clinical stage were independent prognostic risk factors; surgical history, radiotherapy, treatment course of Chinese patent medicine, intravenous drip of Chinese herbal preparation, duration of oral administration of Chinese herbal decoction (CHD), and intervention measures were independent prognostic protective factors. Gender was an independent risk factor for progression, while operation history and oral CHD administration duration were independent protective factors (all P<0.05). Women with stage IIIb-IIIc lung adenocarcinoma had the best outcomes. CONCLUSIONS: Female patients have lower progression risk and better prognoses than male patients, younger patients have higher progression risk but better long-term prognoses than the elderlys, and patients with lower performance status scores are at lower risk for progression and have better prognoses. Comprehensive CM treatments could significantly reduce progression risk, improve prognosis, and prolong survival time for patients with advanced NSCLC. This treatment mode offers additional advantages over supportive care alone.
引用
- Huang XG, Zhu LH, Zhou L, et al. Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study of 855 Cases. Chin J Integr Med. 2020. PMID: 32876856. doi:10.1007/s11655-020-3428-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。